BRAVEHEART INVESTMENT GROUP - Key Persons
Qu joined the Braveheart Board on 16 June 2021 and is a member of the Remuneration and Audit and Committees.
Qu is an experienced entrepreneur, investor and businesswoman with over 30 years of experience in corporate mergers and acquisitions, development and restructuring; and financing and investments. She is currently a non-executive director of IQ-AI Limited and CEO of Morris Commercial Limited.
Non-executive Director (Appointed to the board on 16 June 2021)
Dr Qu Li is an experienced entrepreneur, investor and businesswoman with over 30 years of experience in corporate mergers and acquisitions, development and restructuring; and financing and investments. Qu Li has worked across several business disciplines, including research and development, design and engineering, manufacturing and logistics, marketing and PR; and management and finance. She has led many turnkey transactions ranging from US$5million to US$100 million and she has raised over US$300 million over the past 15 years. Qu is a member of the Group's Remuneration Committee and Audit and Compliance Committee.
Sue joined the Braveheart Board in May 2021 as a non-executive director and is a member of both the Remuneration Committee and the Audit Committee.
Sue has over 20 years of experience in the pharmaceutical and medical device industries, including big pharma and start-up companies, covering project management, early-phase research and development, lab management, regulatory and clinical studies. She is a registered pharmacist with a PhD in drug delivery.
Sue Hagan and Qu Li are considered to be independent directors. The time commitment formally required by the Group is an overriding principal that each director will devote as much time as is required to carry out the roles and responsibilities that the director has agreed to take on. This generally means that Trevor Brown and Vivian Hallam are full time and that, Sue Hagan and Qu Li are part time. Biographical details of the current directors are set out within Principle Six below. Executive and non-executive directors are subject to re-election at intervals of no more than three years. The letters of appointment of all directors are available for inspection at the Company's registered office during normal business hours.
Non-executive Director (Appointed to the board on 18 May 2021)
Sue brings a wide range of experience in research, development and commercialization of medical devices, in-vitro diagnostic (IVD) medical devices, therapeutics and related healthcare products. She led early phase combination drug-device projects with Pfizer and was project manager for the development of a radiopharmaceutical oncology product into a first in-human trial at Aphton Biopharma, a NASDAQ listed immunotherapeutic company, where she led the Research and Development Laboratory. Sue is a member of the Group's Remuneration Committee and Audit and Compliance Committee.
Job Titles:
- Chief Executive Officer
- Executive Director
- Board of Braveheart As a Non - Executive Director
Trevor joined the Board of Braveheart as a non-executive director on 1 April 2014 and was appointed CEO on 24 August 2015.
He has worked as a director in a number of businesses over many years, the most recent being Feedback plc, Management Resource Solutions plc and Advanced Oncotherapy plc. He is currently CEO of IQ-AI Limited and a non-executive director of Chamberlin plc.
Trevor has acted as a CEO, executive director and non-executive director for a wide range of companies in a range of sectors over 40 years. This has provided him with a vast amount of experience through many long term economic and corporate life cycles that mean he is highly qualified to assess the opportunities and risks for both the Group and its portfolio of investee companies. This wide-ranging experience is kept up to date through his continued participation in a variety of businesses where the Group has a holding and in other companies that are unconnected to the Group.
Trevor is also currently a director of IQ-AI Limited and Chamberlin plc. Trevor joined the Board of Braveheart as a Non-executive Director with effect from 1 April 2014 and became the Chief Executive Officer on 21 August 2015.